AstraZeneca plc (AZN) Given a GBX 5,300 Price Target at BNP Paribas
BNP Paribas set a GBX 5,300 ($68.45) price objective on AstraZeneca plc (LON:AZN) in a research report released on Monday. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Several other analysts have also issued reports on AZN. Deutsche Bank AG boosted their price target on AstraZeneca plc from GBX 5,350 ($69.09) to GBX 5,700 ($73.61) and gave the company a buy rating in a report on Monday, May 15th. HSBC Holdings plc reissued a reduce rating and set a GBX 4,200 ($54.24) price target on shares of AstraZeneca plc in a report on Monday, May 15th. Shore Capital raised AstraZeneca plc to a hold rating and set a GBX 4,800 ($61.99) price target for the company in a report on Tuesday, May 16th. Berenberg Bank boosted their price target on AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the company a buy rating in a report on Wednesday, May 17th. Finally, Jefferies Group LLC set a GBX 4,700 ($60.70) price target on AstraZeneca plc and gave the company a neutral rating in a report on Saturday, May 20th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of Hold and a consensus price target of GBX 4,963.82 ($64.11).
Shares of AstraZeneca plc (LON:AZN) opened at 4893.50 on Monday. The stock’s market cap is GBX 61.95 billion. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company’s 50-day moving average price is GBX 4,571.40 and its 200-day moving average price is GBX 4,878.32.
AstraZeneca plc (LON:AZN) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $1.01. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. Equities research analysts anticipate that AstraZeneca plc will post $3.75 earnings per share for the current year.
The business also recently disclosed a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date of this dividend was Thursday, August 10th. This represents a yield of 1.35%.
In related news, insider Nazneen Rahman acquired 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.